Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough

Giliberto, John Paul; Dibildox, Daniel; Meratı, Albert L.

doi:10.1001/jamaoto.2017.1557

Cited by 15 publications

(11 citation statements)

References 18 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, precise roles of laryngeal dysfunction have not been confirmed in chronic cough [94]. Two observational studies suggested the potential benefit of gabapentin therapy for cough patients with abnormal motion of the larynx [95,96]. In clinical experience, it is suggested that speech language and pathology therapy including breathing technique education may be beneficial in chronic cough patients with comorbid laryngeal dysfunction [97].…”

Section: New Concepts To Consider In the Evaluation And Management Ofmentioning

confidence: 99%

Recent progress in the management of chronic cough

Song

McGarvey

2020

Korean J Intern Med

View full text Add to dashboard Cite

Chronic cough is a common clinical condition with significant impact on quality of life and for which effective therapy remains an unmet clinical need. Over the past decade, there has been a major shift in how we approach this problem, driven by better appreciation of the clinical manifestation of chronic cough and an improved understanding of the associated neurobiology. "Cough hypersensitivity syndrome" has been proposed as a new diagnostic term for chronic cough, encompassing different phenotypes of the condition. Accumulating evidence suggests that this new concept is clinically relevant. However, while it is gaining widespread endorsement within the allergy and respiratory community, raising its profile in routine clinical practice is a priority. Thus, the present paper reviews recent progress in our understanding and management of chronic cough, with focus on mechanistic and clinical studies. It also provides detail on knowledge gaps and future research directions.

show abstract

Section: New Concepts To Consider In the Evaluation And Management Ofmentioning

confidence: 99%

Recent progress in the management of chronic cough

Song

McGarvey

2020

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…Although current FDA-approved indications only include adjunct therapy for partial seizures and postherpetic neuralgia, gabapentin has numerous off-label uses, including the treatment of CRC. 75 Thus far, 12 current studies 54,56,[60][61][62][63][64][65][66][67][68][69] show favorable therapeutic effects of gabapentin; however, a standardized dose, optimal treatment duration, and longterm safety data have not been established. The American • PO amitriptyline 10 mg/day given QHS or 10 mL PO codeine/ guaifenesin 10 to 100 mg/5 mL every 6 hours standing dose while awake.…”

Section: Gabapentinmentioning

confidence: 99%

“…Two studies 54,67 saw therapeutic control only after the addition of amitriptyline 54 and botulinum toxin injections every 3 months 67 to gabapentin treatment. The findings of Lee and Woo 67 and Gilberto et al 69 suggest that patients with confirmed findings of motor neuropathy and/ or vocal fold motion asymmetry on laryngeal electromyography or videostroboscopy had an enhanced response to gabapentin therapy. In a case series by Ryan et al, 68 cough severity and cough quality of life improved in 2 patients with Arnold's nerve ear-cough reflex, a rare phenomenon where cough is triggered through mechanical stimulation of the ear.…”

mentioning

confidence: 92%

“…Three case reports 60,61,64 demonstrated patient-reported improvement in cough symptoms at a dose of 200 mg of gabapentin per day (n = 6, mean age = 51 years 60 ; n = 1, mean age = 15 years 61 ; n = 1, mean age = 63 years 64 ), while Madanick et al 66 showed that a dose of 2700 mg per day was required for patient-reported improvement in symptoms (n = 17, mean age = 60.3 years). In 9 out of the 12 trials, 54,56,[60][61][62][65][66][67]69 the dosage of gabapentin was titrated depending on efficacy and tolerability.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Chronic Refractory Cough in Adults: Focus on Neuromodulators and Other Therapeutic Modalities

O’Hare

Rahman

Williams

2020

Journal of Pharmacy Technology

View full text Add to dashboard Cite

Objective: To evaluate the literature and educate health care professionals about the different management options for chronic refractory cough (CRC). Data Sources: Searches were performed through MEDLINE (1966 to July 2020) using OVID and EBSCOhost and EMBASE (1947 to July 2020) using OVID. Search terms included chronic cough, neurogenic cough, neuromodulators, chronic cough management, and chronic cough treatment. References of all relevant articles were further used to obtain additional articles. Study Selection and Data Extraction: This review includes articles in the English language and human trial literature. Twenty-three trials explored the use of oral neuromodulators in the management of CRC. Data Synthesis: CRC is a poorly understood disease that may have a complex neuropathic etiology. Oral neuromodulators, such as amitriptyline, baclofen, gabapentin, and pregabalin, continue to be the most commonly used agents for the management of CRC. Alternative pharmacological therapies such as botulinum toxin, anesthetic agents (benzonatate, lidocaine), and narcotic agents have efficacy data, and further research into effective doses and routes of administration is warranted. Alternative nonpharmacologic therapies more commonly used included speech pathology treatment. Conclusion: Several medication and alternative treatment interventions may be effective in managing CRC. Current studies used wide dosing and titration strategies, making it challenging to standardize therapy. No consistent method of assessing cough reflex was used between studies, as well as a lack of consistent randomization and small sample sizes. Additional research is needed to standardize treatment durations, optimum doses, and place in therapy of the available interventions in the management of CRC.

show abstract

“…A cough is a reflexive inhalation and exhalation against a closed glottis resulting in the forceful expulsion of air as building pressure forces the glottis open. Cough can be classified as acute (lasting up to 8 weeks) or chronic (lasting greater than 8 weeks) [1] , [2] . While acute cough is often self-limited or requires minimal intervention, chronic cough is a common complaint that is often diagnostically and therapeutically challenging in the primary care, otolaryngology, pulmonology, or psychiatric settings.…”

Section: Introductionmentioning

confidence: 99%

Successful use of guanfacine in a patient with chronic refractory cough: A case report

Kirschen

Gabalski

et al. 2017

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Chronic idiopathic cough is a common and often frustrating complaint for patients as well as providers. When common etiologies of cough are ruled out and/or do not respond to usual treatments, neurogenic cough should be considered as a diagnosis of exclusion. Here, we report on a 58-year-old woman with an 8-year history of chronic, treatment-refractory cough of unknown etiology that we diagnosed as neurogenic cough and successfully treated with guanfacine monotherapy, with rapid and durable improvement in symptoms. This case was particularly challenging for a number of reasons, including a distant past smoking history and previous pneumonia, a significant psychiatric history, and a mildly deviated nasal septum and nasal osteophyte, all or some of which could have contributed to the etiology of the cough. This case illustrates that neurogenic cough should be a diagnostic consideration in patients presenting with chronic cough in whom other treatment modalities have failed, and also suggests that the therapeutic use of guanfacine in this clinical setting warrants future investigation.

show abstract

Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough

Abstract: In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy.

Cited by 15 publications

References 18 publications

Recent progress in the management of chronic cough

Recent progress in the management of chronic cough

Treatment of Chronic Refractory Cough in Adults: Focus on Neuromodulators and Other Therapeutic Modalities

Successful use of guanfacine in a patient with chronic refractory cough: A case report

Contact Info

Product

Resources

About